Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
Genital Human Papillomavirus
100%
Hemagglutination Inhibition
100%
Virus-like
50%
HPV16
50%
Human Papillomavirus Types
33%
Cross-protection
33%
Particle-based
33%
Hemagglutination
33%
Human Papillomavirus 11
33%
Amino Acids
16%
Enzyme-linked Immunosorbent Assay (ELISA)
16%
Vaccination
16%
Virion
16%
Type-specific
16%
Cross-reactivity
16%
Human Papillomavirus 33
16%
Rabbit Antiserum
16%
Neutralizing Monoclonal Antibody
16%
Immunology and Microbiology
Wart Virus
100%
Hemagglutination Inhibition
100%
Monospecific Antibody
42%
Virus-Like Particle
42%
Hemagglutination
28%
Cell Surface
28%
Human Papillomavirus Type 18
28%
Human Papillomavirus Type 11
28%
Cross Protection
28%
Human Papillomavirus Type 45
28%
Enzyme-Linked Immunosorbent Assay
14%
Monoclonal Antibody
14%
Virion
14%
Vaccine Efficacy
14%
Human Papillomavirus Type 31
14%
Vaccination Policy
14%
Human Papillomavirus Type 16
14%
Cross-Reactivity
14%
Rabbit Antiserum
14%